Health sciences

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health sciences, Branches of biology, Biotechnology, BioNTech, Drug discovery, Medicinal chemistry, Therapy, Cell therapy

The acquisition strengthens BioNTechs cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program.

Key Points: 
  • The acquisition strengthens BioNTechs cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program.
  • It also expands the Companys cell therapy capabilities and manufacturing footprint in North America, building on its acquisition of Neon Therapeutics in 2020 .
  • All Kite employees at the Gaithersburg facility were offered employment with BioNTech prior to closing.
  • As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company.

Asia-Pacific Cell Therapy Market Analysis Report 2021-2028 by Use-type (Clinical-use, Research-use), & Therapy Type (Autologous, Allogeneic) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Biotechnology, Life sciences, Health sciences, Branches of biology, Stem cells, Biotechnology, Drug discovery, Medicinal chemistry, Therapy, Cell therapy, SWOT analysis

The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific cell therapy market size is expected to reach USD 2.9 billion by 2028.
  • The market is expected to expand at a CAGR of 14.9% from 2021 to 2028.
  • Chapter 3 Cell Therapy Market Variables, Trends, and Scope
    3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
    3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    Chapter 4 Cell Therapy Market: COVID-19 Impact analysis

Five Day Online Computer System Validation Professional Certificate Program (September 6-10, 2021) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Entertainment, Education, Technology, Other Technology, Online, Training, Pharmaceutical industry, Validity, Quality, Health sciences, Clinical data management, Clinical research, Validation, Health, Life sciences, Verification and validation

The "Computer System Validation Boot Camp" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Computer System Validation Boot Camp" training has been added to ResearchAndMarkets.com's offering.
  • A course designed to completely immerse you in computer system validation.
  • This course delivers comprehension of the regulations impacting your systems and hands-on practice writing validation documents.
  • We have designed a computer system validation course that not only meets FDA, ICH, and Eudralex expectations for risk-based validation but also prepares you to implement these practices in your company.

Klick Health and Lakeridge Health Unveil Free Drug Dosage Calculator to Fight Antibiotic-Resistant Bacterial Infections

Retrieved on: 
Wednesday, August 4, 2021
Data Management, Other Science, Medical Supplies, Technology, Research, Managed Care, General Health, Surgery, Pharmaceutical, Other Communications, Marketing, Human Resources, Hospitals, Advertising, Communications, Consulting, Professional Services, Software, Health, Science, Articles, Health sciences, Chemistry, Click, Klick, Lakeridge Health, Vancomycin, Antimicrobial resistance, Lakeridge Health, Klick Health, Klick Group, LAKERIDGE HEALTH, KLICK HEALTH, KLICK GROUP

Today, Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.

Key Points: 
  • Today, Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.
  • The tool, VancoCalc , which has been in use at Lakeridge Health since December 2020, is available for free at www.VancoCalc.com .
  • We are proud to collaborate with Lakeridge Health on this important healthcare innovation, said Klick Medical R&D Scientist and project lead Anirudh Thommandram.
  • The Klick Group of companies Klick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs is an ecosystem of brilliant talent collectively working to maximize their people and clients full potential.

China Pharmaceutical Market and Healthcare Industry Forecast and Analysis Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Pharmaceutical, Health sciences, Health, Contemporary history, COVID-19 pandemic, Occupational safety and health, Pandemics, Public Health Emergency of International Concern, Healthcare industry, Pharmaceutical industry

The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has had quite an impact on the Chinese pharmaceutical and healthcare industry, through industry analysts expect a speedy recovery back to normal levels of demand.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • A SWOT analysis of the Chinese pharmaceutical and healthcare industry.

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Retrieved on: 
Wednesday, August 4, 2021
Health, Hospitals, Manufacturing, Genetics, Other Science, Science, Biotechnology, Life sciences, Health sciences, Branches of biology, Biotechnology, BioNTech, Drug discovery, Medicinal chemistry, Therapy, Cell therapy

View the full release here: https://www.businesswire.com/news/home/20210804005519/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210804005519/en/
    The acquisition strengthens BioNTechs cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program.
  • It also expands the Companys cell therapy capabilities and manufacturing footprint in North America, building on its acquisition of Neon Therapeutics in 2020 .
  • All Kite employees at the Gaithersburg facility were offered employment with BioNTech prior to closing.
  • As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company.

2021 Report on Anterior Uveitis Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, General Health, Health sciences, Medicine, Clinical medicine, Uveitis, Ophthalmology, Mechanism of action

The "Anterior Uveitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anterior Uveitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Anterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

Truveris Appoints Nanette Oddo President and Chief Executive Officer

Retrieved on: 
Wednesday, August 4, 2021
Banking, Software, General Health, Professional Services, Data Management, Technology, Chemicals, Plastics, Insurance, Finance, Other Technology, Health, Consulting, Manufacturing, Health sciences, Clinical pharmacology, Health, Pharmacy, Patient safety, Medical prescription, Symbols, Prescription drug

Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.

Key Points: 
  • Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.
  • A veteran industry leader, Ms. Oddo previously served as Truveris Chief Strategy Officer, spearheading the Companys strategic vision during a period of consistent innovation and growth.
  • "Truveris uniquely bends the cost curve to improve the accessibility and affordability of prescription medications, one of the critical challenges facing healthcare today," said Oddo.
  • Prior to Truveris, Oddo spent twelve years in various leadership roles at Phreesia, the leading intake and patient engagement software solution.

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Immunology, Pharmaceutical industry, Health sciences, Health care, Health, Medication, Antibody, Monoclonal antibodies

The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.

Key Points: 
  • The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.
  • The partnership, which spans several therapeutic areas, will help to rapidly expand EQRxs early-stage pipeline of novel medicines.
  • Were proud to partner with EQRx on their bold mission to reimagine drug development and bring medicines to patients faster and at lower cost, said Carl Hansen, Ph.D., CEO of AbCellera.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Immunology, Pharmaceutical industry, Health sciences, Health care, Health, Medication, Antibody, Monoclonal antibodies, EQRx, AbCellera Biologics Inc., EQRX, ABCELLERA BIOLOGICS INC.

The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.

Key Points: 
  • The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.
  • The partnership, which spans several therapeutic areas, will help to rapidly expand EQRxs early-stage pipeline of novel medicines.
  • Were proud to partner with EQRx on their bold mission to reimagine drug development and bring medicines to patients faster and at lower cost, said Carl Hansen, Ph.D., CEO of AbCellera.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.